APOC3 and metabolic disease: Although hypertriglyceridemia contributes to CVD, it does not independently precipitate β-cell dysfunction, highlighting the complex metabolic interplay and the therapeutic potential of APOC3 as a target in managing CVD risks and metabolic disorders.